Next-Generation Breast Cancer Diagnostic & Screening Market by Product, Diagnostic Technology, Screening Technology, Application, End User

Description

List of Tables

The Next-Generation Breast Cancer Diagnostic & Screening Market was valued at USD 22.81 billion in 2023, expected to reach USD 25.12 billion in 2024, and is projected to grow at a CAGR of 10.91%, to USD 47.11 billion by 2030.

The scope of the next-generation breast cancer diagnostic and screening market encompasses advanced technologies and methodologies aimed at improving early detection, diagnosis, and monitoring of breast cancer, like genomics, proteomics, and liquid biopsy. Necessity for these innovations stems from increasing breast cancer incidence, demand for non-invasive methods, and the need for personalized care. Applications are broad, including genetic tests for assessing cancer risk, early-stage detection using AI-enhanced imaging systems, and real-time monitoring of treatment efficacy. End-users primarily include hospitals, diagnostic laboratories, research institutes, and personalized medicine companies. Market insights reveal growth driven by rising healthcare awareness, technological advancements, increased governmental support, and a shift towards value-based care. Opportunities are evident in expanding AI and machine learning integrations, offering predictive analytics, and developing portable, cost-effective diagnostic tools to reach underserved populations. For businesses, partnership with tech firms and investing in R&D can capitalize on these opportunities. However, certain limitations impede growth, including high costs, stringent regulatory frameworks, and limited access in low-income regions. Challenges also include data privacy concerns and the need for highly skilled professionals. Innovating in areas such as seamless integration of multi-omics data, developing affordable diagnostic kits, and real-time AI analytics represents promising avenues for growth. Moreover, focus on patient-centered care innovations, such as home-based diagnostic solutions, can provide a competitive edge. The market is dynamic, characterized by rapid technology adoption and high competition, which fosters continuous innovation and necessitates robust adaptive strategies. Success often hinges on collaborations, strategic partnerships, and aligning with regulatory changes. Strategic recommendations for businesses involve investing in customer education and engagement, establishing trust through transparency, and prioritizing cross-disciplinary collaborations to foster a holistic approach to understanding and combating breast cancer.

KEY MARKET STATISTICS
Base Year [2023]	USD 22.81 billion
Estimated Year [2024]	USD 25.12 billion
Forecast Year [2030]	USD 47.11 billion
CAGR (%)	10.91%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Next-Generation Breast Cancer Diagnostic & Screening Market

The Next-Generation Breast Cancer Diagnostic & Screening Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Rising prevalence of breast cancer worldwide
- Growing inclination towards early diagnosis and treatment of diseases
- Government initiatives to raise awareness regarding breast cancer
Market Restraints
- Expensive breast cancer diagnostic & screening technologies
Market Opportunities
- Advancements in next-generation breast cancer diagnostic & screening technologies
- Strategic alliances and investments to manufacture innovative breast cancer diagnostic solutions
Market Challenges
- Complexity in manufacturing and stringent regulatory approval process

Porter's Five Forces: A Strategic Tool for Navigating the Next-Generation Breast Cancer Diagnostic & Screening Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Next-Generation Breast Cancer Diagnostic & Screening Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Next-Generation Breast Cancer Diagnostic & Screening Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Next-Generation Breast Cancer Diagnostic & Screening Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Next-Generation Breast Cancer Diagnostic & Screening Market

A detailed market share analysis in the Next-Generation Breast Cancer Diagnostic & Screening Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Next-Generation Breast Cancer Diagnostic & Screening Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Next-Generation Breast Cancer Diagnostic & Screening Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Next-Generation Breast Cancer Diagnostic & Screening Market

A strategic analysis of the Next-Generation Breast Cancer Diagnostic & Screening Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Next-Generation Breast Cancer Diagnostic & Screening Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agendia Inc., Agilent Technologies, Inc., ARTIVION INC., Becton, Dickinson and Company, Benitec Biopharma Ltd, BGI Genomics Co., Ltd., Bio-Rad Laboratories, Inc., Centogene N.V., Danaher Corporation, Epic Sciences, Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, GE HealthCare Technologies, Inc., Hologic, Inc., Illumina, Inc., Invivoscribe, Inc., Koninklijke Philips N.V., Laboratory Corporation of America Holdings, Merck & Co., Inc., Myriad Genetics, Inc., Novartis AG, Pfizer Inc., QIAGEN N.V., Siemens Healthineers AG, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Next-Generation Breast Cancer Diagnostic & Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Product, market is studied across Accessories, Breast Imaging Systems, and Software & Services.
Based on Diagnostic Technology, market is studied across DNA Microarrays, Lab-on-a-Chip & Reverse Transcriptase-PCR, Molecular Diagnostics, Next Generation Sequencing, Protein Microarrays, and qPCR & Multiplexing.
Based on Screening Technology, market is studied across Ionizing Breast Imaging Technologies and Non-ionizing Breast Imaging Technologies. The Ionizing Breast Imaging Technologies is further studied across 3D Breast Tomosynthesis, Analog Mammography, Cone-Beam Computed Tomography (CBCT), Contrast-Enhanced Mammography (CEM), Full-Field Digital Mammography (FFDM), Molecular Breast Imaging/Breast Specific Gamma Imaging (MBI/BSGI), Positron Emission Mammography (PEM), and Positron Emission Tomography and Computed Tomography (PET-CT). The Non-ionizing Breast Imaging Technologies is further studied across Automated Whole-Breast Ultrasound (AWBU), Breast MRI, Breast Thermography, Breast Ultrasound, Electric Impedance Tomography, and Optical Imaging.
Based on Application, market is studied across Cancer Screening, Companion Diagnostics, Risk Analysis, and Therapeutic Monitoring.
Based on End User, market is studied across Breast Care Centers, Diagnostic Imaging Centers, and Hospitals & Clinics.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-5C6F41F5AFF0

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising prevalence of breast cancer worldwide
  - 5.1.1.2. Growing inclination towards early diagnosis and treatment of diseases
  - 5.1.1.3. Government initiatives to raise awareness regarding breast cancer
- 5.1.2. Restraints
  - 5.1.2.1. Expensive breast cancer diagnostic & screening technologies
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in next-generation breast cancer diagnostic & screening technologies
  - 5.1.3.2. Strategic alliances and investments to manufacture innovative breast cancer diagnostic solutions
- 5.1.4. Challenges
  - 5.1.4.1. Complexity in manufacturing and stringent regulatory approval process
5.2. Market Segmentation Analysis
- 5.2.1. Product: Need for advanced breast imaging systems for enhanced clinical outcomes
- 5.2.2. End User: Expanding use of breast cancer diagnostics in hospitals to cater to a wider patient population
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Next-Generation Breast Cancer Diagnostic & Screening Market, by Product

6.1. Introduction
6.2. Accessories
6.3. Breast Imaging Systems
6.4. Software & Services

7. Next-Generation Breast Cancer Diagnostic & Screening Market, by Diagnostic Technology

7.1. Introduction
7.2. DNA Microarrays
7.3. Lab-on-a-Chip & Reverse Transcriptase-PCR
7.4. Molecular Diagnostics
7.5. Next Generation Sequencing
7.6. Protein Microarrays
7.7. qPCR & Multiplexing

8. Next-Generation Breast Cancer Diagnostic & Screening Market, by Screening Technology

8.1. Introduction
8.2. Ionizing Breast Imaging Technologies
- 8.2.1. 3D Breast Tomosynthesis
- 8.2.2. Analog Mammography
- 8.2.3. Cone-Beam Computed Tomography (CBCT)
- 8.2.4. Contrast-Enhanced Mammography (CEM)
- 8.2.5. Full-Field Digital Mammography (FFDM)
- 8.2.6. Molecular Breast Imaging/Breast Specific Gamma Imaging (MBI/BSGI)
- 8.2.7. Positron Emission Mammography (PEM)
- 8.2.8. Positron Emission Tomography and Computed Tomography (PET-CT)
8.3. Non-ionizing Breast Imaging Technologies
- 8.3.1. Automated Whole-Breast Ultrasound (AWBU)
- 8.3.2. Breast MRI
- 8.3.3. Breast Thermography
- 8.3.4. Breast Ultrasound
- 8.3.5. Electric Impedance Tomography
- 8.3.6. Optical Imaging

9. Next-Generation Breast Cancer Diagnostic & Screening Market, by Application

9.1. Introduction
9.2. Cancer Screening
9.3. Companion Diagnostics
9.4. Risk Analysis
9.5. Therapeutic Monitoring

10. Next-Generation Breast Cancer Diagnostic & Screening Market, by End User

10.1. Introduction
10.2. Breast Care Centers
10.3. Diagnostic Imaging Centers
10.4. Hospitals & Clinics

11. Americas Next-Generation Breast Cancer Diagnostic & Screening Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Next-Generation Breast Cancer Diagnostic & Screening Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Next-Generation Breast Cancer Diagnostic & Screening Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
- 14.3.1. GE HealthCare Releases MyBreastAI Suite to Support Clinicians in Accelerating Breast Cancer Detection
- 14.3.2. Exact Sciences Advances Innovative Cancer Technologies and Approaches Through Visionary Collaborations
- 14.3.3. Thermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next Generation Sequencing-Based Testing for Cancer Patients in International Markets
14.4. Strategy Analysis & Recommendation

Companies Mentioned

1. Abbott Laboratories
2. Agendia Inc.
3. Agilent Technologies, Inc.
4. ARTIVION INC.
5. Becton, Dickinson and Company
6. Benitec Biopharma Ltd
7. BGI Genomics Co., Ltd.
8. Bio-Rad Laboratories, Inc.
9. Centogene N.V.
10. Danaher Corporation
11. Epic Sciences, Inc.
12. Exact Sciences Corporation
13. F. Hoffmann-La Roche Ltd.
14. Fujifilm Holdings Corporation
15. GE HealthCare Technologies, Inc.
16. Hologic, Inc.
17. Illumina, Inc.
18. Invivoscribe, Inc.
19. Koninklijke Philips N.V.
20. Laboratory Corporation of America Holdings
21. Merck & Co., Inc.
22. Myriad Genetics, Inc.
23. Novartis AG
24. Pfizer Inc.
25. QIAGEN N.V.
26. Siemens Healthineers AG
27. Thermo Fisher Scientific Inc.